Navigation Links
Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection)
Date:5/19/2010

y other marketed ERT for Type 1 Gaucher disease.

VPRIV was approved by the Food and Drug Administration (FDA) on February 26, 2010, as a long-term treatment for adult and pediatric patients with Type 1 Gaucher disease. It has also been granted accelerated assessment by the European Medicines Agency (EMA) in the European Union (EU). Shire expects to launch VPRIV in the EU in the second half of 2010, and in other countries beginning in 2011.

"It is a tremendous honor to be recognized by NORD," said Sylvie Gregoire, President of Shire HGT. "This award embodies the spirit of our organization-every employee at Shire is dedicated to developing and bringing forward new products, services and support offerings which can make a positive impact on patients' daily lives. We look forward to collaborating with NORD on many other important initiatives in the future."

Important Safety Information for VPRIV

The most serious adverse reactions seen with VPRIV were hypersensitivity reactions. Infusion-related reactions were the most commonly observed adverse reactions in patients treated with VPRIV in clinical studies. The most commonly observed symptoms of infusion-related reactions were: headache, dizziness, low or high blood pressure, nausea, tiredness and weakness, and fever. Generally the infusion-related reactions were mild and, in treatment-naive patients, onset occurred mostly during the first 6 months of treatment and tended to occur less frequently with time. Adverse reactions more commonly seen in pediatric patients compared to those observed in adult patients (>10% difference) include rash, upper respiratory tract infection, prolonged activated partial thromboplastin time, and fever.

As with all therapeutic proteins, there is a
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. INTUNIV(TM) - Shire Files Suit Against Actavis Elizabeth LLC and Actavis Inc.
2. Shires Replenished Portfolio Drives Excellent Quarterly Performance
3. Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals
4. Shire Supports Rare Disease Day 2010
5. Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease
6. Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA)
7. Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease
8. New Shire Board Member
9. Shire Secures European Wide Label Extension for FOSRENOL(R) in Chronic Kidney Disease
10. New CapSure™ Cleanroom Wiper from Berkshire Corporation Captures and Retains 42 Times More Contaminant Particles
11. Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Although most natural and synthetic processes prefer to ... potential or energyit is within the realm of ... experience constant changes in energy and phases, such ... These conditions allow humans to regulate their body ... rumble with seismic activity. , But even ...
(Date:7/24/2014)... July 24, 2014 Research and Markets ... Genomics and Proteomics Analytical Instruments Market 2014-2018" report ... Genomics is the study of the ... of the structure and functions of proteomes or sets ... and technology. Genomics involves the mapping of genes and ...
(Date:7/24/2014)... 2014 SRI International has been awarded a ... of Allergy and Infectious Diseases (NIAID), part of the ... potential therapies for HIV infection and AIDS. The contract ... AIDS and the complications and opportunistic infections associated with ... transmission of HIV. According to the ...
(Date:7/24/2014)... Francisco, CA (PRWEB) July 24, 2014 ... to be semi-finalists in Livestrong’s Big C Competition. Out ... Health are each headed to the semi-final round. In ... Livestrong’s exclusive three-month accelerator program, complete with mentoring from ... , As part of the angelMD commitment to ...
Breaking Biology Technology:New approach to form non-equilibrium structures 2Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 33 angelMD Startups Make Livestrong Big C Semi-finals 2
... /PRNewswire-Asia-FirstCall/ -- China Sky One Medical,Inc. ("China Sky ... CSKI ), a leading,fully integrated pharmaceutical company producing ... today announced that the Company,s,Chief Financial Officer, Mr. ... at the upcoming Roth 21st Annual OC Growth ...
... COTTAGE, N.Y., Feb. 5 XTL,Biopharmaceuticals Ltd. (Nasdaq: ... February 3, 2009 the Company received a letter from ... outstanding ordinary shares requesting the,convening of an extraordinary shareholders, ... address and approve the following matters: , ...
... Va., Feb. 5, 2009 AMERIGROUP Chairman and Chief ... on legislation expanding the State Children,s Health Insurance Program ... of America,s children deserve a healthy start in life, ... see a family doctor and get the healthcare they ...
Cached Biology Technology:China Sky One Medical, Inc. CFO to Present at Roth Conference 2China Sky One Medical, Inc. CFO to Present at Roth Conference 3Corrected: XTL Biopharmaceuticals to Convene Extraordinary Shareholders' Meetings after Receipt of Shareholder Letter 2AMERIGROUP Praises Expansion of State Children's Health Insurance Program (SCHIP) 2
(Date:7/25/2014)... For the first time, Spanish researchers have detected an ... coli cells are introduced into a droplet of ... the sodium chloride crystallisation to create biomineralogical biosaline 3D ... rehydrating the material, bacteria are revived. The discovery was ... made the cover of the Astrobiology journal ...
(Date:7/24/2014)... Scientists at The New York Stem Cell Foundation ... creating a viable cell replacement therapy for multiple ... For the first time, NYSCF scientists generated induced ... of patients with primary progressive multiple sclerosis and ... these stem cells into becoming oligodendrocytes, the myelin-forming ...
(Date:7/24/2014)... 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced ... control Phase 3 study of Zerenex (ferric citrate), the ... treatment of hyperphosphatemia in patients with end-stage renal disease ... iRon delivery with FErric CiTrate in EsrD) was published ... Society of Nephrology ( JASN ). ...
Breaking Biology News(10 mins):Bacteria manipulate salt to build shelters to hibernate 2NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4
... for the body to make estrogen, are no longer a ... Ghosh lab at the Hauptman-Woodward Medical Research Institute (HWI) in ... three-dimensional structure of aromatase is the first time that scientists ... In fact, the Ghosh lab has determined the ...
... shows the resistance of the avian flu virus to a ... selection, with researchers documenting the trend in more than 30 ... Influenza A subtype dubbed H5N1, is evolving a resistance to ... two classes of antiviral drugs used to prevent and treat ...
... drug therapy called fenobam has shown promising initial results and ... with Fragile X syndrome (FXS). Findings of the open ... and the University of California, Davis, Medical Center are to ... Journal of Medical Genetics . Results of ...
Cached Biology News:HWI scientist first in world to unravel structure of key breast cancer target enzyme 2HWI scientist first in world to unravel structure of key breast cancer target enzyme 3Avian flu becoming more resistant to antiviral drugs, says University of Colorado study 2Avian flu becoming more resistant to antiviral drugs, says University of Colorado study 3Promising new drug being evaluated as possible treatment option for fragile X syndrome 2
... CL3 series is designed to enhance ... clinical applications at a reasonable cost. ... quick connect rotors and various biocontainment ... interface allows you to control and ...
... tradition of progressive centrifuge design and manufacturing, ... Centra-CL3 and Centra-CL3R (refrigerated) general purpose models ... Quality Control Over Sample Preparation , The ... to 99 protocols and has speed and ...
p230 trans Golgi Purified Anti-Human clone 15, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
... DNA Polymerase I Large (Klenow) Fragment, ... that lacks both the 5´→3´ and the ... coli DNA Polymerase I (1,2). It is ... in strand displacement amplification (5). Klenow Fragment, ...
Biology Products: